LEXARIA BIOSCIENCE CORP. Capitalized Interest Costs, Including Allowance for Funds Used During Construction
LEXARIA BIOSCIENCE CORP. (LEXX) reported Capitalized Interest Costs, Including Allowance for Funds Used During Construction of $13.62 thousand for the 3-month period ending 2023-11-30, per its 10-Q filed 2024-01-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InterestCostsIncurredCapitalized · last filed 2024-01-12
- LEXARIA BIOSCIENCE CORP. capitalized interest costs, including allowance for funds used during construction for the quarter ending 2023-11-30 was $13.62K.
- LEXARIA BIOSCIENCE CORP. capitalized interest costs, including allowance for funds used during construction for fiscal 2023 was $5.18K.
| Period end | Capitalized Interest Costs, Including Allowance for Funds Used During Construction 3 month | Capitalized Interest Costs, Including Allowance for Funds Used During Construction 12 month |
|---|---|---|
| 2023-11-30 | $13.62K 10-Q · filed 2024-01-12 | |
| 2023-08-31 | $5.18K 10-K · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |